Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation.

An SP1-specific inhibitor, plicamycin, effectively suppresses CRPC growth in vivo. The study reveal the existence of SCLPC in admixed PCa pathology, which may mediate tumor relapse, and establish SP1 and translation elongation as actionable therapeutic targets for CRPC.

For cell suspensions, researchers obtained cell measurements with Countstar (model not specified) before single-cell analysis for the cancer-model experiments.